2023
DOI: 10.13040/ijpsr.0975-8232.14(9).4292-03
|View full text |Cite
|
Sign up to set email alerts
|

Untitled

Abstract: Rosuvastatin is a widely used lipid-lowering medication that belongs to the class of "Statins" whereas Teneligiptin is a novel potent drug that belongs to the class of "DPP-4 inhibitors" which is used for the treatment of Type 2 Diabetes mellitus. The FDA recently approved the combination of these two drugs in 2021 since it proved to be highly effective for treating dyslipidemia associated with Type 2 Diabetes mellitus. Forced degradation studies have been performed on Rosuvastatin and Teneligliptin separately… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 20 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?